{{Rsnum
|rsid=1399180
|Gene=GATA3
|Chromosome=10
|position=8098719
|Orientation=plus
|GMAF=0.2273
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 63.7 | 34.5 | 1.8
| HCB | 92.5 | 6.8 | 0.8
| JPT | 85.6 | 12.6 | 1.8
| YRI | 17.2 | 49.7 | 33.1
| ASW | 35.1 | 47.4 | 17.5
| CHB | 92.5 | 6.8 | 0.8
| CHD | 88.8 | 11.2 | 0.0
| GIH | 85.1 | 12.9 | 2.0
| LWK | 16.4 | 49.1 | 34.5
| MEX | 70.7 | 29.3 | 0.0
| MKK | 21.3 | 49.0 | 29.7
| TSI | 69.3 | 30.7 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1399180
|Name_s=
|Gene_s=GATA3
|Feature=Intron
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109404
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1399180
|overall_frequency_n=98
|overall_frequency_d=128
|overall_frequency=0.765625
|n_genomes=50
|n_genomes_annotated=0
|n_haplomes=82
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}